Adjuvant Capital

Memo Therapeutics AG, based in Basel, Switzerland, specializes in antibody discovery and immune repertoire analysis through its innovative MemoMAB platform. This technology enables the creation of a recombinant in vitro copy of an individual’s B cell and antibody repertoire, resulting in unique and extensive libraries that reflect a person's immune response. These libraries are anticipated to contain a significant number of relevant and rare antibodies, opening new avenues for immune repertoire analysis and antibody discovery. Memo Therapeutics employs its MemoMAB platform in proprietary antibody lead discovery programs and offers it for collaboration with other entities, enhancing the potential for novel therapeutic developments.

Curevo Vaccine is clinical stage biotech company dedicated to developing next generation vaccines that bring effectiveness, safety, tolerability, and advanced production capabilities to the market - quickly and efficiently. Curevo's lead product, a sub-unit Zoster (Shingles) Vaccine, has completed Phase I (90 subject trial). Results are showing a promising safety profile and the desired immune responses. We are targeting a unique position in the $7B Varicella Zoster Virus vaccine market.

54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

VitriVax is a biotech startup that develops a vaccine formulation platform. VitriVax's proprietary technology, created at the University of Colorado with the support of over $5M from NIH, NSF and the State of Colorado, and most recently, $2.2M from the Bill and Melinda Gates Foundation, makes human and animal vaccines more effective, more affordable, and more accessible globally. VitriVax is headquartered in Boulder, Colorado.

Pulmocide Ltd is a London-based company established in 2007 that specializes in developing inhaled medicines aimed at treating serious viral and fungal infections of the respiratory tract. The company focuses on creating a new generation of antifungal drugs tailored for inhalation, which enhances the delivery of medication directly to the lungs while reducing systemic exposure. This targeted approach is designed to improve efficacy against respiratory aspergillosis and minimize systemic toxicities, thereby offering safe and effective treatment options for patients with acute and chronic respiratory diseases.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, that specializes in the development of gene editing therapeutics targeting life-threatening diseases caused by neurotropic viruses. Founded in 2015, the company employs CRISPR-based technology to create innovative treatments that aim to eradicate or disrupt viral genes in human patients. Excision is committed to advancing these therapeutics into safe and effective medicines, addressing significant medical needs and improving the quality of life for individuals affected by viral infections.

Frontier Nutrition, Inc. is a company based in Dover, Delaware, that focuses on developing, manufacturing, and marketing fortified packaged food products aimed at addressing the nutritional needs of low and middle-income households in underserved communities globally. Established in 2016, Frontier Nutrition creates innovative and culturally relevant recipes that cater to traditional diets while optimizing for taste, nutrition, and affordability. The company’s mission is to combat early life and maternal malnutrition by providing low-cost and convenient food options for families facing challenges such as limited access to healthcare, transportation, and clean water. Through cutting-edge research in pediatric nutrition and behavioral marketing, Frontier Nutrition strives to improve the overall well-being and sustainable living standards of families in frontier markets.

Univercells SA, founded in 2013 and based in Gosselies, Belgium, specializes in the design, development, and implementation of single-use bioprocess solutions for biomanufacturing. The company offers a comprehensive range of services, including the design and construction of manufacturing facilities, as well as the maintenance and supply of bulk active pharmaceutical ingredients (APIs). With a focus on vaccines and biologics, Univercells employs innovative engineering techniques that significantly reduce investment needs by over 75% and lower production costs by up to 90%. Their approach integrates three manufacturing steps—cell culture under perfusion, clarification, and capture—into a simulated continuous mode, enhancing efficiency in the production of antibodies, proteins, and vaccines. Additionally, Univercells has established a strategic partnership with Takeda Pharmaceutical Company to further advance its capabilities in the biomanufacturing sector.

Minervax is pursuing the development of a vaccine against Group B streptococcus (GBS) infections by utilizing a particular fusion protein, which has proved to elicit good protective immunity. A vaccine including this fusion protein will likely elicit protective immunity against many clinically relevant GBS strains.

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women’s sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, a vaginal pH regulator for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women. Evofem Biosciences, Inc. is headquartered in San Diego, California.

ChromaCode, Inc. is a molecular diagnostics company based in Carlsbad, California, that specializes in developing innovative testing solutions for infectious diseases, cancer, and non-invasive prenatal testing (NIPT) using proprietary technology derived from Caltech. The company enhances the performance of quantitative polymerase chain reaction (qPCR) instruments, achieving a five-fold increase in multiplexing capabilities while maintaining cost-effectiveness. ChromaCode employs advanced bioinformatics techniques and patented mathematical methods to improve signal processing, enabling laboratories to conduct comprehensive testing of multiple targets in a single sample. Additionally, the company offers products such as the HDPCR Tick-Borne Pathogen Panel, which detects various tick-borne pathogens through a multiplex polymerase chain reaction test. Founded in 2012, ChromaCode draws expertise from professionals with backgrounds in leading organizations such as Illumina and Google[x].

54gene develops a pan-African biobank to identify new drug targets, and develop diagnostics and treatments for diseases. The company targets multiple disease states, including cancer, cardiovascular disease, and neuro-degenerative disease. It also provides genetic testing and molecular diagnostics services. The company was founded in 2019 and is based in San Francisco, California with an additional offices in Lagos, Nigeria.

Codagenix, Inc. is a biotechnology company based in Farmingdale, New York, focused on developing live-attenuated viral vaccines for various diseases, including influenza, dengue, respiratory syncytial virus, and polio. The company utilizes its proprietary Synthetic Attenuated Virus Engineering (SAVE) technology, which employs computer-based rational design to construct viral genomes, allowing for the creation of innovative vaccine strains. In addition to human vaccines, Codagenix also provides agricultural and companion animal vaccines. The company has also been engaged in the development of a COVID-19 vaccine, showcasing its commitment to addressing current health challenges. Codagenix was incorporated in 2009 and emphasizes the use of synthetic biology in its vaccine development processes.

AN2 Therapeutics, Inc. is a biopharmaceutical company based in Menlo Park, California, dedicated to the research, development, and commercialization of innovative medicines for infectious diseases. Incorporated in 2017, the company is currently focused on its lead product candidate, epetraborole, a once-daily oral treatment aimed at addressing chronic non-tuberculous mycobacterial lung disease, a condition with significant unmet medical needs. AN2 Therapeutics is also involved in strategic partnerships, notably with Brii Biosciences, to enhance its development capabilities and reach. The company’s commitment is to leverage modern biomedical expertise to deliver transformational therapies for patients suffering from serious infections.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

InDevR, Inc. is a biotechnology company based in Boulder, Colorado, that specializes in developing and marketing innovative life science instrumentation and assay products for virus and microorganism analysis. The company offers a range of products, including the Virus Counter for virus quantification, FluChip for rapid pathogen detection, and ViroPrep, which prepares samples for downstream analysis. Additionally, InDevR provides the miPLEX platform for multiplexed immunoassays, the Vidia fluorescence microarray imaging system, and the ampliPHOX Reader for interpreting microarray images. Their technologies support vaccine characterization and facilitate tracking of seasonal and emerging influenza viruses, catering to clients involved in vaccine research, development, and manufacturing. InDevR was incorporated in 2002.

X-Vax Technology is a biotechnology company focused on the preclinical and clinical development of vaccines against pathogens that cause mucosal infections such as herpes, influenza, tuberculosis and HIV, affecting hundreds of millions of people around the globe. They believe that inducing antibodies that mediate the killing of infected cells will provoke an entirely new and effective immune response – so that they can finally beat these pathogens. The company was founded in 2015 and based in Jupiter, Florida.